MiR-223-3p and miR-122-5p as circulating biomarkers for plaque instability

BackgroundIn this study, we discovered and validated candidate microRNA (miRNA) biomarkers for coronary artery disease (CAD).MethodCandidate tissue-derived miRNAs from atherosclerotic plaque material in patients with stable coronary artery disease (SCAD) (n=14) and unstable coronary artery disease (UCAD) (n=25) were discovered by qPCR-based arrays. We validated differentially expressed miRNAs, along with seven promising CAD-associated miRNAs from the literature, in the serum of two large cohorts (n=395 and n=1000) of patients with SCAD and UCAD and subclinical atherosclerosis (SubA) and controls, respectively.ResultFrom plaque materials (discovery phase), miR-125b-5p and miR-193b-3p were most upregulated in SCAD, whereas miR-223-3p and miR-142-3p were most upregulated in patients with UCAD. Subsequent validation in serum from patients with UCAD, SCAD, SubA and controls demonstrated significant upregulation of miR-223-3p, miR-133a-3p, miR-146-3p and miR-155-5p. The ischaemia-related miR-499-5p was also highly upregulated in patients with UCAD compared with the other groups (SCAD OR 20.63 (95% CI 11.16 to 38.15), SubA OR 96.10 (95% CI 40.13 to 230.14) and controls OR 15.73 (95% CI 7.80 to 31.72)). However, no significant difference in miR-499-5p expression was observed across SCAD, SubA and controls. MiR-122-5p was the only miRNA to be significantly upregulated in the serum of both patients with UCAD and SCAD.ConclusionIn conclusion, miR-122-5p and miR-223-3p might be markers of plaque instability.

Download Full-text

Polymer free drug-eluting stents versus durable polymer drug-eluting stents in elective percutaneous coronary interventions in patients with stable coronary artery disease patients

QJM ◽

10.1093/qjmed/hcaa041.020 ◽

2020 ◽

Vol 113 (Supplement_1) ◽

Author(s):

S M A Altoukhy ◽

A A A Rezq ◽

B A M Anany ◽

W A M Elhamady ◽

M F Metwally ◽

...

Keyword(s):

Coronary Artery Disease ◽

Coronary Artery ◽

Inflammatory Response ◽

Stable Coronary Artery Disease ◽

Drug Eluting Stents ◽

P Value ◽

Effort Angina ◽

Significant Difference ◽

Drug Eluting ◽

Artery Disease

Abstract Aim To compare the inflammatory response of polymer-free versus permanent polymer drug-eluting stents in patients with stable coronary artery disease undergoing elective PCI, and the effect of this inflammatory response on the 6 month clinical outcomes. Methods This randomized prospective comparative study was conducted on 100 patients with stable coronary artery disease planned for elective PCI divided into 50 patients with deployed permanent polymer DES (PP-DES) groups and 50 patients with polymer free DES (PF-DES). Blood samples were taken to assess serum level of hsCRP before the procedure and the first day after the procedure. The target end points were the recurrence of effort angina, incidence of target lesion revascularization (TLR) over a period of 6 months and the inflammatory response by measuring the percentage of rise in hsCRP level. Results There was no statistically significant difference in the clinical outcome in the first six months between the patients who had PP-DES and the patients who had PF-DES regarding recurrence of effort angina (p-value = 0.822) and TLR (p-value = 0.727), with no patients developing myocardial infarction or stent thrombosis. There was a statistically significant inflammatory response after stent deployment in both groups represented by a significant rise in the serum level of hsCRP on the first day after the procedure in both groups (p-value < 0.001), but there was no statistically significant difference in the inflammatory response between PP-DES and PF-DES (p-value = 0.978). The number of patients having recurrence of anginal symptoms and TLR with hsCRP rise ≥ 11.36% was higher than those having the same with hsCRP < 11.36%. However, this difference was not statistically significant regarding recurrence of anginal symptoms (p = 0.057) and TLR (p = 0.092). Conclusion The PF-DES was proved to be non-inferior to PP-DES regarding the short-term clinical outcome and the early inflammatory response. It was concluded that the presence of polymeric coating in PP-DES did not add to the magnitude of the inflammatory response and it did not significantly increase the incidence of recurrence of anginal symptoms and TLR in this group of patients.

Download Full-text

Atherogenic dyslipidaemia and cardiovascular events in patients with diabetes or pre-diabetes and stable coronary artery disease: a prospective, cohort study

BMJ Open ◽

10.1136/bmjopen-2020-037340 ◽

2021 ◽

Vol 11 (1) ◽

pp. e037340

Author(s):

Jing-Lu Jin ◽

Ye-Xuan Cao ◽

Li-Guo Wu ◽

Xiang-Dong You ◽

Na Guo ◽

...

Keyword(s):

Coronary Artery Disease ◽

Cohort Study ◽

Coronary Artery ◽

Glucose Metabolism ◽

Cardiovascular Events ◽

Stable Coronary Artery Disease ◽

Significant Difference ◽

Atherogenic Dyslipidaemia ◽

Artery Disease ◽

Stable Cad

ObjectiveThe aim of the study was to investigate the impacts of triglyceride (TG) and high-density lipoprotein cholesterol (HDL-C) dyslipidaemia on prognosis in coronary artery disease (CAD) patients with different glucose metabolism status.DesignAn observational cohort study.Setting/participantsA total of 3057 patients with stable CAD were consecutively enrolled and divided into three groups according to different glucose metabolism status. Atherogenic dyslipidaemia (AD) was defined as TG ≥1.7 mmol/L and HDL-C <1.0 mmol/L for men or <1.3 mmol/L for women. The patients were further classified into six subgroups by status of AD. All subjects were followed up for the cardiovascular events (CVEs).Primary outcome measuresThe primary endpoints were cardiovascular mortality, non-fatal myocardial infarction and non-fatal stroke.ResultsDuring a median follow-up of 6.1 years, 308 (10.1%) CVEs occurred. No significant difference in the occurrence of CVEs was observed between normal glucose regulation (NGR) and pre-diabetes (pre-DM) groups (HR: 1.25, 95% CI 0.89 to 1.76) while DM group presented 1.45-fold higher risk of CVEs (HR: 1.45, 95% CI 1.02 to 2.05). When the participants were categorised according to combined status of two parameters, the cardiovascular risk was significantly elevated in pre-DM or DM plus AD group compared with the NGR plus non-AD group (HR: 1.76, 95% CI 1.10 to 2.80 and HR: 1.87, 95% CI 1.17 to 2.98).ConclusionsThe present study suggested that the presence of AD might affect the prognosis in patients with DM or pre-DM and stable CAD.

Download Full-text

Impact of free fatty acids on prognosis in coronary artery disease patients under different glucose metabolism status

Cardiovascular Diabetology ◽

10.1186/s12933-019-0936-8 ◽

2019 ◽

Vol 18 (1) ◽

Cited By ~ 3

Author(s):

Jing-Lu Jin ◽

Ye-Xuan Cao ◽

Hui-Hui Liu ◽

Hui-Wen Zhang ◽

Yuan-Lin Guo ◽

...

Keyword(s):

Coronary Artery Disease ◽

Fatty Acids ◽

Coronary Artery ◽

Glucose Metabolism ◽

Free Fatty Acids ◽

Cox Model ◽

Stable Coronary Artery Disease ◽

P Value ◽

Significant Difference ◽

Artery Disease

Abstract Background The aim of the present study is to examine the effects of free fatty acids (FFAs) on major cardiovascular events (MACEs) in patients with stable coronary artery disease (CAD) and different glucose metabolism status. Methods In this study, we consecutively enrolled 5443 patients from March 2011 to May 2015. Patients were categorized according to both status of glucose metabolism status [diabetes mellitus (DM), pre-diabetes (Pre-DM), normal glycaemia regulation (NGR)] and FFAs levels. All subjects were followed up for the occurrence of the MACEs. Results During a median of 6.7 years’ follow-up, 608 MACEs occurred. A twofold higher FFAs level was independently associated with MACEs after adjusting for confounding factors [Hazard Ratio (HR): 1.242, 95% confidence interval (CI) 1.084–1.424, p value = 0.002]. Adding FFAs to the Cox model increased the C-statistic by 0.015 (0.005–0.027). No significant difference in MACEs was observed between NGR and Pre-DM groups (p > 0.05). When patients were categorized by both status of glucose metabolism and FFAs levels, medium and high FFAs were associated with significantly higher risk of MACEs in Pre-DM [1.736 (1.018–2.959) and 1.779 (1.012–3.126), all p-value < 0.05] and DM [2.017 (1.164–3.494) and 2.795 (1.619–4.824), all p-value < 0.05]. Conclusions The present data indicated that baseline FFAs levels were associated with the prognosis in DM and Pre-DM patients with CAD, suggesting that FFAs may be a valuable predictor in patients with impaired glucose metabolism.

Download Full-text

Sonoclot Analysis in Coronary Artery Surgery: A Comparison Between Patients With Unstable Coronary Artery Disease Treated With Enoxaparin Before Surgery and Patients With Stable Coronary Artery Disease Not Treated With Enoxaparin

Journal of Cardiothoracic and Vascular Anesthesia ◽

10.1053/j.jvca.2007.12.024 ◽

2008 ◽

Vol 22 (5) ◽

pp. 670-674 ◽

Cited By ~ 2

Author(s):

Hilde Pleym ◽

Alexander Wahba ◽

Lise Bjella ◽

Roar Stenseth

Keyword(s):

Coronary Artery Disease ◽

Coronary Artery ◽

Stable Coronary Artery Disease ◽

Coronary Artery Surgery ◽

Unstable Coronary Artery Disease ◽

Artery Disease

Download Full-text

INDICATIONS OF PRESCRIPTION OF STATINS IN TERTIARY CARE CENTRE OF NORTH INDIA

International Journal of Medical and Biomedical Studies ◽

10.32553/ijmbs.v6i1.2392 ◽

2022 ◽

Vol 6 (1) ◽

Author(s):

Shilpa Atwal ◽

Jitender Thakur

Keyword(s):

Coronary Artery Disease ◽

Coronary Artery ◽

Primary Prevention ◽

Secondary Prevention ◽

Stable Coronary Artery Disease ◽

Tertiary Care ◽

North India ◽

Tertiary Care Centre ◽

Unstable Coronary Artery Disease ◽

Artery Disease

Background: To determine the indications for which statins are being prescribed Methods: Study was conducted on Patients with indications for statins presenting to cardiology OPD,Medicine OPD and Endocrinology OPD and started on statins at PGIMER, Chandigarh, within a period of 9 months. Results: In our study, out of 243 prescriptions, 55.1%(n=134) were prescribed statins for secondary prevention and 44.9%(n=109) had statins prescribed for primary prevention. Overall coronary artery disease (37.03%) was the leading indication followed by Diabetes mellitus without ASCVD(70.64%).Other indications of secondary preventionincluded newly diagnosed statin naïve patients diagnosed with stable coronary artery disease ,unstable coronary artery disease /acute coronary artery disease , ischemic cardiovascular accidentsand peripheral arterial disease .64.22 percent patients in primary prevention group were diabetics in our study . Concluded: We concluded that secondary prevention was found to the more common indication of statin prescription than primary prevention (ratio 1.22:1). Keywords: Statin, CAD, Prevention

Download Full-text

Differences Between Local Investigator and Core Laboratory Interpretation of the Admission Electrocardiogram in a Large Multicenter Trial of Patients With Unstable Coronary Artery Disease

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(97)83923-x ◽

1998 ◽

Vol 31 (2) ◽

pp. 48A

Author(s):

L Holmvang

Keyword(s):

Coronary Artery Disease ◽

Coronary Artery ◽

Multicenter Trial ◽

Unstable Coronary Artery Disease ◽

Artery Disease ◽

Local Investigator

Download Full-text

Markers of Hemostatic Activation in Affected Coronary Arteries during Angioplasty

Thrombosis and Haemostasis ◽

10.1055/s-0038-1648940 ◽

1994 ◽

Vol 72 (05) ◽

pp. 672-675 ◽

Cited By ~ 14

Author(s):

Nicolas W Shammas ◽

Michael J Cunningham ◽

Richard M Pomearntz ◽

Charles W Francis

Keyword(s):

Coronary Artery Disease ◽

Coronary Artery ◽

Venous Blood ◽

Balloon Inflation ◽

Blood Samples ◽

Hemostatic System ◽

Significant Difference ◽

Hemostatic Markers ◽

Artery Disease ◽

High Doses

SummaryTo characterize the extent of early activation of the hemostatic system following angioplasty, we obtained blood samples from the involved coronary artery of 11 stable angina patients during the procedure and measured sensitive markers of thrombin formation (fibrino-peptide A, prothrombin fragment 1.2, and soluble fibrin) and of platelet activation ((3-thromboglobulin). Levels of hemostatic markers in venous blood obtained from 14 young individuals with low pretest probability for coronary artery disease were not significantly different from levels in venous blood or intracoronary samples obtained prior to angioplasty. Also, there was no translesional (proximal and distal to the lesion) gradient in any of the hemostatic markers before or after angioplasty in samples obtained between 18 and 21 min from the onset of the first balloon inflation. Furthermore, no significant difference was noted between angioplasty and postangioplasty intracoronary concentrations. We conclude that intracoronary hemostatic activation does not occur in the majority of patients during and immediately following coronary angioplasty when high doses of heparin and aspirin are administered.

Download Full-text

The Effect of Antiplatelet Drugs on Plasma Betathromboglobulin in Coronary Artery Disease

10.1055/s-0038-1665677 ◽

1979 ◽

Cited By ~ 1

Author(s):

P Han ◽

A Turpie ◽

E Genton ◽

M Gent

Keyword(s):

Coronary Artery Disease ◽

Coronary Artery ◽

Crossover Trial ◽

Specific Protein ◽

Antiplatelet Drugs ◽

Significant Difference ◽

Pre Treatment ◽

Artery Disease ◽

Therapeutic Doses ◽

Granule Release

Platelets play a role in the development and complications of coronary artery disease (CAD) and a number of abnormalities of platelet function which can be corrected by antiplatelet drugs have been described. Betathromboglobulin (BTG), a platelet-specific protein which is released from α-granules during platelet activation is significantly elevated in patients with angiographically demonstrated CAD (51.0 ± 31.0 ng/ml., n = 50) compared to normal (28.0 ± 8.0 ng/ml., n = 70) p < 0.001. The effect of sulphinpyrazone (800 mg.) or aspirin (1200 mg.)/dipyridamole (200 mg.) on plasma BTG in CAD was studied in a blind prospective crossover trial in 25 patients. Mean BTG concentration pre-treatment was 52.3 ng/ml. and after 1 month’s treatment with placebo, sulphinpyrazone or aspirin/dipyridamole mean plasma BTG concentrations were 53.5, 49.6 and 56.7 ng/ml. respectively. Analysis of variance showed no significant difference between the means (p > 0.1) . This study confirms increased plasma BTG concentrations in patients with CAD and indicates that therapeutic doses of these antiplatelet drugs do not significantly effect the BTG level and thus appear not to prevent α-granule release in CAD.

Download Full-text